These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11315008)

  • 21. Study designs for evaluating different efficacy and effectiveness aspects of vaccines.
    Halloran ME; Struchiner CJ; Longini IM
    Am J Epidemiol; 1997 Nov; 146(10):789-803. PubMed ID: 9384199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Statistical aspects of fish vaccination trials.
    Jarp J; Tverdal A
    Dev Biol Stand; 1997; 90():311-20. PubMed ID: 9270859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines.
    Longini IM; Datta S; Halloran ME
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Dec; 13(5):440-7. PubMed ID: 8970471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimation of vaccine efficacy in the presence of waning: application to cholera vaccines.
    Durham LK; Longini IM; Halloran ME; Clemens JD; Nizam A; Rao M
    Am J Epidemiol; 1998 May; 147(10):948-59. PubMed ID: 9596473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mumps vaccine effectiveness in primary schools and households, the Netherlands, 2008.
    Snijders BE; van Lier A; van de Kassteele J; Fanoy EB; Ruijs WL; Hulshof F; Blauwhof A; Schipper M; van Binnendijk R; Boot HJ; de Melker HE; Hahné SJ
    Vaccine; 2012 Apr; 30(19):2999-3002. PubMed ID: 22381073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reproductive numbers, epidemic spread and control in a community of households.
    Goldstein E; Paur K; Fraser C; Kenah E; Wallinga J; Lipsitch M
    Math Biosci; 2009 Sep; 221(1):11-25. PubMed ID: 19559715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomizing research participants: promoting balance and concealment in small samples.
    Matthews EE; Cook PF; Terada M; Aloia MS
    Res Nurs Health; 2010 Jun; 33(3):243-53. PubMed ID: 20499394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Constrained randomization in a therapeutic efficacy trial.
    Tamura RN; Mills BJ; Lovelace JK
    Biometrics; 1993 Mar; 49(1):249-58. PubMed ID: 8513107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incorporating founder virus information in vaccine field trials.
    Follmann D; Huang CY
    Biometrics; 2015 Jun; 71(2):386-96. PubMed ID: 25773491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On estimation of vaccine efficacy using validation samples with selection bias.
    Scharfstein DO; Halloran ME; Chu H; Daniels MJ
    Biostatistics; 2006 Oct; 7(4):615-29. PubMed ID: 16556610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A discrete-time model for the statistical analysis of infectious disease incidence data.
    Rampey AH; Longini IM; Haber M; Monto AS
    Biometrics; 1992 Mar; 48(1):117-28. PubMed ID: 1316178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiation.
    Gilbert PB; Sun Y
    Biostatistics; 2005 Jul; 6(3):374-94. PubMed ID: 15831584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantifying the magnitude of baseline covariate imbalances resulting from selection bias in randomized clinical trials.
    Berger VW
    Biom J; 2005 Apr; 47(2):119-27; discussion 128-39. PubMed ID: 16389910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On vaccine efficacy and reproduction numbers.
    Farrington CP
    Math Biosci; 2003 Sep; 185(1):89-109. PubMed ID: 12900143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maximizing statistical power in group-randomized vaccine trials.
    Riggs T; Koopman JS
    Epidemiol Infect; 2005 Dec; 133(6):993-1008. PubMed ID: 16274496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficient generation of constrained block allocation sequences.
    Salama I; Ivanova A; Qaqish B
    Stat Med; 2008 Apr; 27(9):1421-8. PubMed ID: 17729381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and analysis issues in cluster-randomized trials of interventions against infectious diseases.
    Hayes RJ; Alexander ND; Bennett S; Cousens SN
    Stat Methods Med Res; 2000 Apr; 9(2):95-116. PubMed ID: 10946429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Balancing statistical and ethical considerations in planning clinical trials: recommendations for response-adaptive randomization urn designs.
    Piccorelli AV; Fraker SA
    J Biopharm Stat; 2018; 28(6):1105-1118. PubMed ID: 29442610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measuring HIV vaccine efficacy.
    Hernández-Suárez CM
    Stat Med; 2005 Apr; 24(7):983-92. PubMed ID: 15568204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.